Fampridine-SR

Phase 3Small molecule

AAcorda Therapeutics

Fampridine-SR is one of 166 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

MemoryActive, not recruiting

Multiple SclerosisActive, not recruiting

Optic NeuritisActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

MemoryPhase 2

Active, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Optic NeuritisPhase 1

Active, not recruiting

Spinal Cord InjuryPhase 3

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Fampridine-SR

AAcorda Therapeutics

Phase 3

7 2

Betaseron

Bayer

Preclinical

16 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Myfortic

Novartis

Preclinical

—9

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis7 trials

Study of Oral Fampridine-SR in Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 3·NCT00127530·300 enrolled

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Completed·AAcorda Therapeutics·Phase 3·NCT00483652·240 enrolled

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 3·NCT00654927·177 enrolled

Show 4 more trials

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Completed·AAcorda Therapeutics·Phase 2·NCT00053417·206 enrolled

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Completed·AAcorda Therapeutics·Phase 3·NCT00648908·269 enrolled

Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?

Completed·LLondon Health Sciences Centre·Phase 2/3·NCT01667497·60 enrolled

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Completed·AAcorda Therapeutics·Phase 3·NCT00649792·214 enrolled

Memory3 trials

Influence of Fampridine on Working Memory in Healthy Young Subjects

Completed·PProf. Dominique de Quervain, MD·Phase 2·NCT04652557·44 enrolled

Influence of Fampridine on Working Memory in Healthy Subjects

Withdrawn·PProf. Dominique de Quervain, MD·Phase 2·NCT04516603

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Recruiting·UUniversity of Basel·Phase 2·NCT06751784·38 enrolled

Spinal Cord Injury2 trials

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Completed·AAcorda Therapeutics·Phase 3·NCT00041717·213 enrolled

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Completed·AAcorda Therapeutics·Phase 3·NCT01683838·204 enrolled

Optic Neuritis1 trial

Fampridine-SR and Optic Neuritis Recovery

Unknown status·CCourtney Casserly·Phase 1·NCT04148781·20 enrolled

Cognitive impairment1 trial

Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment

Terminated·PProf. Dominique de Quervain, MD·N/A·NCT05274477·8 enrolled

1 more indication

Outcome1 trial

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

Completed·UUniversity of Southern Denmark·Phase 4·NCT01656148·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Fampridine-SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fampridine-SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fampridine-SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acorda Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAcorda Therapeutics

Fampridine-SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis7 trials

Memory3 trials

Spinal Cord Injury2 trials

Optic Neuritis1 trial

Cognitive impairment1 trial

Outcome1 trial

References

Drug Info

Quick Facts

Related News